CYSLTR2 and neoplasm: BAP1 mutations were associated with Class 2 tumors (p < 0.0001), PRAME(+) status (p < 0.0001), increased patient age (p < 0.0001), increased tumor diameter (p < 0.0001), increased tumor thickness (p < 0.0001), ciliary body involvement (p < 0.0001), mutations in GNA11 (p = 0.01), PLCB4 (p = 0.02) and CYSLTR2 (p = 0.02), and absence of mutations in GNAQ (p < 0.0001).